This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SB-751689

GlaxoSmithKline plc

Drug Names(s): Calcilytic Compound, ronacaleret

Description: NPS is developing Calcilytics, which are orally active, small molecules for treating osteoporosis. SB-751689 is the lead Calcilytic. Calcilytics antagonize calcium receptors on parathyroid glands resulting in a transient release of the body’s own stores of parathyroid hormone (PTH). In this way, calcilytics have the potential to produce the same therapeutic effect as PREOS, but through oral administration rather than through injection. They thus represent an attractive potential follow-on product to PREOS.

Preclinical studies showed that the increased levels of PTH achieved by calcilytics were equivalent to those achieved by PTH injection and therefore may also have the ability to cause bone growth.

Deal Structure: In 1993, a Collaborative Research and License Agreement was signed by NPS and GSK. Under the terms of the Collaborative Research and License Agreement with GSK, NPS will receive royalties on global product sales and has the right to co-promote products resulting from the collaboration with GSK in North America.

In August 2011, NPS and GlaxoSmithKline announced a new agreement expanding the licensed field of research for ronacaleret. GSK will be responsible for all development, manufacturing and commercialization of ronacaleret. NPS will be entitled to development milestones and royalties on any future sales of ronacaleret. GSK will no longer have rights to other calcilytic compounds discovered or developed under the 1993 agreement.

NPS and Shire
In January 2015, Shire and NPS Pharmaceuticals entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of...See full deal structure in Biomedtracker

Partners: Shire Pharmaceuticals Group PLC


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug